{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:33:55Z","timestamp":1772120035748,"version":"3.50.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T00:00:00Z","timestamp":1625356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T00:00:00Z","timestamp":1625356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"Guangdong Basic and Applied Basic Research Fund","award":["2021A1515010339"],"award-info":[{"award-number":["2021A1515010339"]}]},{"name":"Guangzhou Science Technology and Innovation Commission","award":["201807010042"],"award-info":[{"award-number":["201807010042"]}]},{"name":"Guangzhou Science Technology and Innovation Commission","award":["201704030087"],"award-info":[{"award-number":["201704030087"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22077145"],"award-info":[{"award-number":["22077145"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s12026-021-09204-5","type":"journal-article","created":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T13:02:10Z","timestamp":1625403730000},"page":"378-390","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine derivative attenuates lupus nephritis with less effect to thymocyte development"],"prefix":"10.1007","volume":"69","author":[{"given":"Fengjiao","family":"Wei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqing","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huanpeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuyan","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhonghua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bolan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xixin","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuan","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4367-6943","authenticated-orcid":false,"given":"Zhaofeng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,7,4]]},"reference":[{"issue":"11","key":"9204_CR1","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1002\/art.1780251101","volume":"25","author":"EM Tan","year":"1982","unstructured":"Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271\u20137. https:\/\/doi.org\/10.1002\/art.1780251101.","journal-title":"Arthritis Rheum"},{"issue":"1","key":"9204_CR2","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/cei.12296","volume":"179","author":"OP Rekvig","year":"2015","unstructured":"Rekvig OP. Anti-dsDNA antibodies as a classification criterion and a diagnostic marker for systemic lupus erythematosus: critical remarks. Clin Exp Immunol. 2015;179(1):5\u201310. https:\/\/doi.org\/10.1111\/cei.12296.","journal-title":"Clin Exp Immunol"},{"issue":"11","key":"9204_CR3","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/ni1254","volume":"6","author":"LE Harrington","year":"2005","unstructured":"Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, Weaver CT. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005;6(11):1123\u201332. https:\/\/doi.org\/10.1038\/ni1254.","journal-title":"Nat Immunol"},{"issue":"2","key":"9204_CR4","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1177\/135245859900500206","volume":"5","author":"D Matusevicius","year":"1999","unstructured":"Matusevicius D, KivisaKk P, He B, Kostulas N, Ozenci V, Fredrikson S, Link H. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler. 1999;5(2):101\u20134. https:\/\/doi.org\/10.1177\/135245859900500206.","journal-title":"Mult Scler"},{"issue":"1","key":"9204_CR5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1136\/gut.52.1.65","volume":"52","author":"S Fujino","year":"2003","unstructured":"Fujino S, Andoh A, Bamba S, Ogawa A, Hata K, Araki Y, Bamba T, Fujiyama Y. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003;52(1):65\u201370. https:\/\/doi.org\/10.1136\/gut.52.1.65.","journal-title":"Gut"},{"issue":"1","key":"9204_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/ar1478","volume":"7","author":"E Lubberts","year":"2005","unstructured":"Lubberts E, Koenders MI. Berg WBVDJAR, Therapy: The role of T-cell interleukin-17 in conducting destructive arthritis: lessons from animal models. Arthritis Res Ther. 2005;7(1):29\u201337. https:\/\/doi.org\/10.1186\/ar1478.","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"9204_CR7","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.immuni.2004.08.018","volume":"21","author":"JK Kolls","year":"2004","unstructured":"Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity. 2004;21(4):467\u201376. https:\/\/doi.org\/10.1016\/j.immuni.2004.08.018.","journal-title":"Immunity"},{"issue":"5","key":"9204_CR8","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.4049\/jimmunol.0900385","volume":"183","author":"Z Zhang","year":"2009","unstructured":"Zhang Z, Kyttaris VC, Tsokos GC. The role of IL-23\/IL-17 axis in lupus nephritis. J Immunol. 2009;183(5):3160\u20139. https:\/\/doi.org\/10.4049\/jimmunol.0900385.","journal-title":"J Immunol"},{"issue":"2","key":"9204_CR9","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1177\/0961203310389100","volume":"20","author":"SA Apostolidis","year":"2011","unstructured":"Apostolidis SA, Crispin JC, Tsokos GC. IL-17-producing T cells in lupus nephritis. Lupus. 2011;20(2):120\u20134. https:\/\/doi.org\/10.1177\/0961203310389100.","journal-title":"Lupus"},{"key":"9204_CR10","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1007\/978-1-60761-720-4_11","volume":"900","author":"PS Biswas","year":"2012","unstructured":"Biswas PS, Kang K, Gupta S, Bhagat G, Pernis AB. A murine autoimmune model of rheumatoid arthritis and systemic lupus erythematosus associated with deregulated production of IL-17 and IL-21. Methods Mol Biol. 2012;900:233\u201351. https:\/\/doi.org\/10.1007\/978-1-60761-720-4_11.","journal-title":"Methods Mol Biol"},{"issue":"3","key":"9204_CR11","doi-asserted-by":"publisher","first-page":"e58161","DOI":"10.1371\/journal.pone.0058161","volume":"8","author":"Z Wen","year":"2013","unstructured":"Wen Z, Xu L, Xu W, Yin Z, Gao X, Xiong S. Interleukin-17 expression positively correlates with disease severity of lupus nephritis by increasing anti-double-stranded DNA antibody production in a lupus model induced by activated lymphocyte derived DNA. PLoS ONE. 2013;8(3):e58161. https:\/\/doi.org\/10.1371\/journal.pone.0058161.","journal-title":"PLoS ONE"},{"issue":"4","key":"9204_CR12","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1002\/art.27334","volume":"62","author":"MC Genovese","year":"2010","unstructured":"Genovese MC, Van den Bosch F, Roberson SA, Bojin S, Biagini IM, Ryan P, Sloan-Lancaster J. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a phase I randomized, double-blind, placebo-controlled, proof-of-concept study. Arthritis Rheum. 2010;62(4):929\u201339. https:\/\/doi.org\/10.1002\/art.27334.","journal-title":"Arthritis Rheum"},{"issue":"13","key":"9204_CR13","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1056\/NEJMoa1109997","volume":"366","author":"C Leonardi","year":"2012","unstructured":"Leonardi C, Matheson R, Zachariae C, Cameron G, Li L, Edson-Heredia E, Braun D, Banerjee S. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366(13):1190\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1109997.","journal-title":"N Engl J Med"},{"issue":"4","key":"9204_CR14","doi-asserted-by":"publisher","first-page":"395","DOI":"10.2174\/1568010042634497","volume":"3","author":"M Ja","year":"2004","unstructured":"Ja M. Recent advances in the mechanisms of action and physiological functions of the retinoid-related orphan receptors (RORs). Curr Drug Targets Inflamm Allergy. 2004;3(4):395\u2013412. https:\/\/doi.org\/10.2174\/1568010042634497.","journal-title":"Curr Drug Targets Inflamm Allergy"},{"key":"9204_CR15","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1034\/j.1600-065X.2003.00074.x","volume":"195","author":"G Eberl","year":"2003","unstructured":"Eberl G, Littman DR. The role of the nuclear hormone receptor RORgammat in the development of lymph nodes and Peyer\u2019s patches. Immunol Rev. 2003;195:81\u201390.","journal-title":"Immunol Rev"},{"issue":"6","key":"9204_CR16","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/j.immuni.2005.03.011","volume":"22","author":"T Egawa","year":"2005","unstructured":"Egawa T, Eberl G, Taniuchi I, Benlagha K, Geissmann F, Hennighausen L, Bendelac A, Littman DR. Genetic evidence supporting selection of the Valpha14i NKT cell lineage from double-positive thymocyte precursors. Immunity. 2005;22(6):705\u201316. https:\/\/doi.org\/10.1016\/j.immuni.2005.03.011.","journal-title":"Immunity"},{"issue":"5475","key":"9204_CR17","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1126\/science.288.5475.2369","volume":"288","author":"Z Sun","year":"2000","unstructured":"Sun Z, Unutmaz D, Zou YR, Sunshine MJ, Pierani A, Brenner-Morton S, Mebius RE, Littman DR. Requirement for RORgamma in thymocyte survival and lymphoid organ development. Science. 2000;288(5475):2369\u201373. https:\/\/doi.org\/10.1126\/science.288.5475.2369.","journal-title":"Science"},{"issue":"3","key":"9204_CR18","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1097\/00002820-200202000-00013","volume":"62","author":"E Ueda","year":"2002","unstructured":"Ueda E, Kurebayashi S, Sakaue M, Backlund M, Koller B, Jetten AM. High incidence of T-cell lymphomas in mice deficient in the retinoid-related orphan receptor RORgamma. Cancer Res. 2002;62(3):901\u20139. https:\/\/doi.org\/10.1097\/00002820-200202000-00013.","journal-title":"Cancer Res"},{"issue":"2","key":"9204_CR19","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1084\/jem.20041257","volume":"201","author":"CL Langrish","year":"2005","unstructured":"Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basha B. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med. 2005;201(2):233\u201340. https:\/\/doi.org\/10.1084\/jem.20041257.","journal-title":"J Exp Med"},{"issue":"7","key":"9204_CR20","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1038\/nm.2817","volume":"18","author":"JP Sherlock","year":"2012","unstructured":"Sherlock JP, Joyce-Shaikh B, Turner SP, Chao C-C, Sathe M. IL-23 induces spondyloarthropathy by acting on ROR-\u03b3t+ CD3+CD4-CD8- entheseal resident T cells. Nat Med. 2012;18(7):1069\u201376. https:\/\/doi.org\/10.1038\/nm.2817.","journal-title":"Nat Med"},{"issue":"6","key":"9204_CR21","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1615\/CritRevImmunol.v26.i6.10","volume":"26","author":"H Xie","year":"2006","unstructured":"Xie H, Huang Z, Wang R, Sun Z. Regulation of thymocyte survival by transcriptional coactivators. Crit Rev Immunol. 2006;26(6):475\u201386. https:\/\/doi.org\/10.1615\/CritRevImmunol.v26.i6.10.","journal-title":"Crit Rev Immunol"},{"issue":"9","key":"9204_CR22","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1002\/eji.201242740","volume":"42","author":"JR Huh","year":"2012","unstructured":"Huh JR, Littman DR. Small molecule inhibitors of ROR\u03b3t: targeting Th17 cells and other applications. Eur J Immunol. 2012;42(9):2232\u20137. https:\/\/doi.org\/10.1002\/eji.201242740.","journal-title":"Eur J Immunol"},{"issue":"5","key":"9204_CR23","doi-asserted-by":"publisher","first-page":"e91127","DOI":"10.1172\/jci.insight.91127","volume":"2","author":"G Christine","year":"2017","unstructured":"Christine G, Alessandro P, Laure HM, Diethilde T, Jens S. Retinoic-acid-orphan-receptor-C inhibition suppresses Th17 cells and induces thymic aberrations. JCI Insight. 2017;2(5):e91127. https:\/\/doi.org\/10.1172\/jci.insight.91127.","journal-title":"JCI Insight"},{"issue":"10","key":"9204_CR24","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1038\/ni.3832","volume":"18","author":"Z He","year":"2017","unstructured":"He Z, Ma J, Wang R, Zhang J, Huang Z, Wang F, Sen S, Rothenberg EV, Sun Z. A two-amino-acid substitution in the transcription factor ROR\u03b3t disrupts its function in TH17 differentiation but not in thymocyte development. Nat Immunol. 2017;18(10):1128\u201338. https:\/\/doi.org\/10.1038\/ni.3832.","journal-title":"Nat Immunol"},{"issue":"6","key":"9204_CR25","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.cell.2006.07.035","volume":"126","author":"II Ivanov","year":"2006","unstructured":"Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, Cua DJ, Littman DR. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell. 2006;126(6):1121\u201333. https:\/\/doi.org\/10.1016\/j.cell.2006.07.035.","journal-title":"Cell"},{"issue":"7344","key":"9204_CR26","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/nature09978","volume":"472","author":"JR Huh","year":"2011","unstructured":"Huh JR, Leung MWL, Huang P, Ryan DA, Krout MR. Digoxin and its derivatives suppress TH17 cell differentiation by antagonizing RORgammat activity. Nature. 2011;472(7344):486\u201390. https:\/\/doi.org\/10.1038\/nature09978.","journal-title":"Nature"},{"issue":"7344","key":"9204_CR27","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/nature10075","volume":"472","author":"LA Solt","year":"2011","unstructured":"Solt LA, Kumar N, Nuhant P, Wang Y, Lauer JL, Liu J, Istrate MA, Kamenecka TM, Roush WR, Vidovi\u0107 D, et al. Suppression of TH17 differentiation and autoimmunity by a synthetic ROR ligand. Nature. 2011;472(7344):491\u20134. https:\/\/doi.org\/10.1038\/nature10075.","journal-title":"Nature"},{"issue":"4","key":"9204_CR28","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.immuni.2014.04.004","volume":"40","author":"S Xiao","year":"2014","unstructured":"Xiao S, Yosef N, Yang J, Wang Y, Zhou L, Zhu C, Wu C, Baloglu E, Schmidt D, Ramesh R, et al. Small-molecule RORgammat antagonists inhibit T helper 17 cell transcriptional network by divergent mechanisms. Immunity. 2014;40(4):477\u201389. https:\/\/doi.org\/10.1016\/j.immuni.2014.04.004.","journal-title":"Immunity"},{"issue":"1","key":"9204_CR29","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/13543776.2017.1236918","volume":"27","author":"SM Bronner","year":"2017","unstructured":"Bronner SM, Zbieg JR, Crawford JJ. ROR\u03b3 antagonists and inverse agonists: a patent review. Expert Opin Ther Pat. 2017;27(1):101\u201312. https:\/\/doi.org\/10.1080\/13543776.2017.1236918.","journal-title":"Expert Opin Ther Pat"},{"issue":"9","key":"9204_CR30","doi-asserted-by":"publisher","first-page":"e0137711","DOI":"10.1371\/journal.pone.0137711","volume":"10","author":"Q Ding","year":"2015","unstructured":"Ding Q, Zhao M, Yu B, Bai C, Huang Z. Identification of tetraazacyclic compounds as novel potent inhibitors antagonizing RORgammat activity and suppressing Th17 cell differentiation. PLoS ONE. 2015;10(9):e0137711. https:\/\/doi.org\/10.1371\/journal.pone.0137711.","journal-title":"PLoS ONE"},{"key":"9204_CR31","doi-asserted-by":"publisher","first-page":"103077","DOI":"10.1016\/j.bioorg.2019.103077","volume":"90","author":"C Lao","year":"2019","unstructured":"Lao C, Zhou X, Chen H, Wei F, Huang Z, Bai C. 5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidine derivatives as inhibitors of full-length RORgammat. Bioorg Chem. 2019;90:103077. https:\/\/doi.org\/10.1016\/j.bioorg.2019.103077.","journal-title":"Bioorg Chem"},{"issue":"5","key":"9204_CR32","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1182\/blood-2008-05-078154","volume":"112","author":"J Zhu","year":"2008","unstructured":"Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. Blood. 2008;112(5):1557\u201369. https:\/\/doi.org\/10.1182\/blood-2008-05-078154.","journal-title":"Blood"},{"issue":"4","key":"9204_CR33","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1097\/MAJ.0b013e31827f4ee3","volume":"346","author":"N Maroz","year":"2013","unstructured":"Maroz N. Segal MSJAJotMS: Lupus nephritis and end-stage kidney disease. Am J Med Sci. 2013;346(4):319\u201323.","journal-title":"Am J Med Sci"},{"issue":"8","key":"9204_CR34","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1038\/nrrheum.2011.88","volume":"7","author":"GK Bertsias","year":"2011","unstructured":"Bertsias GK, Boumpas DT. Connective tissue diseases: lupus nephritis-winning a few battles but not the war. Nat Rev Rheumatol. 2011;7(8):441\u20132. https:\/\/doi.org\/10.1038\/nrrheum.2011.88.","journal-title":"Nat Rev Rheumatol"},{"issue":"19","key":"9204_CR35","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1056\/NEJM199805073381906","volume":"338","author":"BH Hahn","year":"1998","unstructured":"Hahn BH. Antibodies to DNA. N Engl J Med. 1998;338(19):1359. https:\/\/doi.org\/10.1056\/NEJM199805073381906.","journal-title":"N Engl J Med"},{"issue":"3","key":"9204_CR36","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1074\/jbc.M207577200","volume":"278","author":"S Aggarwal","year":"2003","unstructured":"Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem. 2003;278(3):1910\u20134. https:\/\/doi.org\/10.1074\/jbc.M207577200.","journal-title":"J Biol Chem"},{"issue":"6","key":"9204_CR37","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1517\/14728222.11.6.737","volume":"11","author":"Z Huang","year":"2007","unstructured":"Huang Z, Xie H, Wang R, Sun Z. Retinoid-related orphan receptor \u03b3t is a potential therapeutic target for controlling inflammatory autoimmunity. Expert Opin Ther Targets. 2007;11(6):737\u201343. https:\/\/doi.org\/10.1517\/14728222.11.6.737.","journal-title":"Expert Opin Ther Targets"},{"issue":"11","key":"9204_CR38","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1038\/sj.cdd.4401085","volume":"9","author":"AM Jetten","year":"2002","unstructured":"Jetten AM, Ueda E. Retinoid-related orphan receptors (RORs): roles in cell survival, differentiation and disease. Cell Death Differ. 2002;9(11):1167\u201371. https:\/\/doi.org\/10.1038\/sj.cdd.4401085.","journal-title":"Cell Death Differ"},{"issue":"11","key":"9204_CR39","doi-asserted-by":"publisher","first-page":"5668","DOI":"10.4049\/jimmunol.164.11.5668","volume":"164","author":"YW He","year":"2000","unstructured":"He YW, Beers C, Deftos ML, Ojala EW, Forbush KA. Bevan MJJJoI: Down-regulation of the orphan nuclear receptor ROR\u03b3t is essential for T lymphocyte maturation. J Immunol. 2000;164(11):5668\u201374. https:\/\/doi.org\/10.4049\/jimmunol.164.11.5668.","journal-title":"J Immunol"},{"issue":"12","key":"9204_CR40","doi-asserted-by":"publisher","first-page":"1679","DOI":"10.1210\/mend.9.12.8614404","volume":"9","author":"MA Ortiz","year":"1995","unstructured":"Ortiz MA, Piedrafita FJ, Pfahl M, Maki R. TOR: a new orphan receptor expressed in the thymus that can modulate retinoid and thyroid hormone signals. Mol Endocrinol. 1995;9(12):1679\u201391. https:\/\/doi.org\/10.1210\/mend.9.12.8614404.","journal-title":"Mol Endocrinol"},{"issue":"18","key":"9204_CR41","doi-asserted-by":"publisher","first-page":"10132","DOI":"10.1073\/pnas.97.18.10132","volume":"97","author":"S Kurebayashi","year":"2000","unstructured":"Kurebayashi S, Ueda E, Sakaue M, Patel DD, Medvedev A, Zhang F. Jetten AMJPotNAoSotUSoA: Retinoid-related orphan receptor gamma (RORgamma ) is essential for lymphoid organogenesis and controls apoptosis during thymopoiesis. Proc Natl Acad Sci U S A. 2000;97(18):10132\u20137. https:\/\/doi.org\/10.1073\/pnas.97.18.10132.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"9204_CR42","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.1016\/j.autrev.2016.07.036","volume":"15","author":"M Liljevald","year":"2016","unstructured":"Liljevald M, Rehnberg M, S\u00f6derberg M, Ramneg\u00e5rd M, B\u00f6rjesson J. Retinoid-related orphan receptor \u03b3 (ROR\u03b3) adult induced knockout mice develop lymphoblastic lymphoma. Autoimmun Rev. 2016;15(11):1162\u201370. https:\/\/doi.org\/10.1016\/j.autrev.2016.07.036.","journal-title":"Autoimmun Rev"},{"issue":"9","key":"9204_CR43","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1002\/eji.201242740","volume":"42","author":"JR Huh","year":"2012","unstructured":"Huh JR, Littman DR. Small molecule inhibitors of RORgammat: targeting Th17 cells and other applications. Eur J Immunol. 2012;42(9):2232\u20137. https:\/\/doi.org\/10.1002\/eji.201242740.","journal-title":"Eur J Immunol"},{"issue":"3","key":"9204_CR44","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jdermsci.2019.03.002","volume":"93","author":"C Imura","year":"2019","unstructured":"Imura C, Ueyama A, Sasaki Y, Shimizu M, Furue Y, Tai N, Tsujii K, Katayama K, Okuno T, Shichijo M, et al. A novel RORgammat inhibitor is a potential therapeutic agent for the topical treatment of psoriasis with low risk of thymic aberrations. J Dermatol Sci. 2019;93(3):176\u201385. https:\/\/doi.org\/10.1016\/j.jdermsci.2019.03.002.","journal-title":"J Dermatol Sci"},{"issue":"6","key":"9204_CR45","doi-asserted-by":"publisher","first-page":"3800","DOI":"10.4049\/jimmunol.175.6.3800","volume":"175","author":"H Xie","year":"2005","unstructured":"Xie H, Sadim MS, Sun Z. RORgammat recruits steroid receptor coactivators to ensure thymocyte survival. J Immunol. 2005;175(6):3800\u20139. https:\/\/doi.org\/10.4049\/jimmunol.175.6.3800.","journal-title":"J Immunol"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-021-09204-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12026-021-09204-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-021-09204-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,5]],"date-time":"2021-08-05T03:19:45Z","timestamp":1628133585000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12026-021-09204-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,4]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["9204"],"URL":"https:\/\/doi.org\/10.1007\/s12026-021-09204-5","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.22921\/v1","asserted-by":"object"}]},"ISSN":["0257-277X","1559-0755"],"issn-type":[{"value":"0257-277X","type":"print"},{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,4]]},"assertion":[{"value":"13 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were approved and supervised by the Ethics Committee of ZSSOM on the Laboratory Animal Care (No. 2017\u2013273) and were performed according to the guidelines of the Institute for Laboratory Animal Research of Sun Yat-sen University Laboratory Animal Center (Guangzhou, China).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}